Literature DB >> 24285179

EEF1A2 inactivates p53 by way of PI3K/AKT/mTOR-dependent stabilization of MDM4 in hepatocellular carcinoma.

Rossella Pellegrino1, Diego F Calvisi, Olaf Neumann, Venkatesh Kolluru, Josephine Wesely, Xin Chen, Chunmei Wang, Torsten Wuestefeld, Sara Ladu, Nahla Elgohary, Justo Lorenzo Bermejo, Bernhard Radlwimmer, Martin Zörnig, Lars Zender, Frank Dombrowski, Matthias Evert, Peter Schirmacher, Thomas Longerich.   

Abstract

UNLABELLED: Mouse Double Minute homolog 4 (MDM4) gene up-regulation often occurs in human hepatocellular carcinoma (HCC), but the molecular mechanisms responsible for its induction remain poorly understood. Here we investigated the role of the phosphoinositide-3-kinase/v-akt murine thymoma viral oncogene homolog/mammalian target of rapamycin (PI3K/AKT/mTOR) axis in the regulation of MDM4 levels in HCC. The activity of MDM4 and the PI3K/AKT/mTOR pathway was modulated in human HCC cell lines by way of silencing and overexpression experiments. Expression of main pathway components was analyzed in an AKT mouse model and human HCCs. MDM4 inhibition resulted in growth restraint of HCC cell lines both in vitro and in vivo. Inhibition of the PI3K-AKT and/or mTOR pathways lowered MDM4 protein levels in HCC cells and reactivated p53-dependent transcription. Deubiquitination by ubiquitin-specific protease 2a and AKT-mediated phosphorylation protected MDM4 from proteasomal degradation and increased its protein stability. The eukaryotic elongation factor 1A2 (EEF1A2) was identified as an upstream inducer of PI3K supporting MDM4 stabilization. Also, we detected MDM4 protein up-regulation in an AKT mouse model and a strong correlation between the expression of EEF1A2, activated/phosphorylated AKT, and MDM4 in human HCC (each rho > 0.8, P < 0.001). Noticeably, a strong activation of this cascade was associated with shorter patient survival.
CONCLUSION: The EEF1A2/PI3K/AKT/mTOR axis promotes the protumorigenic stabilization of the MDM4 protooncogene in human HCC by way of a posttranscriptional mechanism. The activation level of the EEF1A2/PI3K/AKT/mTOR/MDM4 axis significantly influences the survival probability of HCC patients in vivo and may thus represent a promising molecular target.
© 2014 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24285179      PMCID: PMC4115286          DOI: 10.1002/hep.26954

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  33 in total

Review 1.  Twenty years of p53 research: structural and functional aspects of the p53 protein.

Authors:  P May; E May
Journal:  Oncogene       Date:  1999-12-13       Impact factor: 9.867

2.  Surfing the p53 network.

Authors:  B Vogelstein; D Lane; A J Levine
Journal:  Nature       Date:  2000-11-16       Impact factor: 49.962

3.  Isolation and identification of the human homolog of a new p53-binding protein, Mdmx.

Authors:  A Shvarts; M Bazuine; P Dekker; Y F Ramos; W T Steegenga; G Merckx; R C van Ham; W van der Houven van Oordt; A J van der Eb; A G Jochemsen
Journal:  Genomics       Date:  1997-07-01       Impact factor: 5.736

4.  The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation.

Authors:  J Momand; G P Zambetti; D C Olson; D George; A J Levine
Journal:  Cell       Date:  1992-06-26       Impact factor: 41.582

5.  Low incidence of p53 mutations in European hepatocellular carcinomas with heterogeneous mutation as a rare event.

Authors:  S Kubicka; C Trautwein; H Schrem; H Tillmann; M Manns
Journal:  J Hepatol       Date:  1995-10       Impact factor: 25.083

6.  MDMX: a novel p53-binding protein with some functional properties of MDM2.

Authors:  A Shvarts; W T Steegenga; N Riteco; T van Laar; P Dekker; M Bazuine; R C van Ham; W van der Houven van Oordt; G Hateboer; A J van der Eb; A G Jochemsen
Journal:  EMBO J       Date:  1996-10-01       Impact factor: 11.598

Review 7.  Mdm-2: "big brother" of p53.

Authors:  J Momand; G P Zambetti
Journal:  J Cell Biochem       Date:  1997-03-01       Impact factor: 4.429

Review 8.  The tumor suppressor gene TP53: implications for cancer management and therapy.

Authors:  Severine Seemann; Daniela Maurici; Magali Olivier; Claude Caron de Fromentel; Pierre Hainaut
Journal:  Crit Rev Clin Lab Sci       Date:  2004       Impact factor: 6.250

Review 9.  Molecular epidemiology of human cancer.

Authors:  S P Hussain; C C Harris
Journal:  Recent Results Cancer Res       Date:  1998

10.  Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma.

Authors:  Cécile Guichard; Giuliana Amaddeo; Sandrine Imbeaud; Yannick Ladeiro; Laura Pelletier; Ichrafe Ben Maad; Julien Calderaro; Paulette Bioulac-Sage; Mélanie Letexier; Françoise Degos; Bruno Clément; Charles Balabaud; Eric Chevet; Alexis Laurent; Gabrielle Couchy; Eric Letouzé; Fabien Calvo; Jessica Zucman-Rossi
Journal:  Nat Genet       Date:  2012-05-06       Impact factor: 38.330

View more
  25 in total

Review 1.  [EEF1A2 inhibits the p53 function in hepatocellular carcinoma via PI3K/AKT/mTOR-dependent stabilization of MDM4].

Authors:  T Longerich
Journal:  Pathologe       Date:  2014-11       Impact factor: 1.011

2.  PI3K/AKT/mTOR-dependent stabilization of oncogenic far-upstream element binding proteins in hepatocellular carcinoma cells.

Authors:  Jana Samarin; Vibor Laketa; Mona Malz; Stephanie Roessler; Ilan Stein; Elad Horwitz; Stephan Singer; Eleni Dimou; Antonio Cigliano; Michaela Bissinger; Christine Susanne Falk; Xin Chen; Steven Dooley; Eli Pikarsky; Diego Francesco Calvisi; Carsten Schultz; Peter Schirmacher; Kai Breuhahn
Journal:  Hepatology       Date:  2016-01-14       Impact factor: 17.425

Review 3.  Emerging Role of the Pathologist in Precision Medicine for HCC.

Authors:  Thomas Longerich; Peter Schirmacher
Journal:  Dig Dis Sci       Date:  2019-04       Impact factor: 3.199

4.  DNA-PKcs deficiency sensitizes the human hepatoma HepG2 cells to cisplatin and 5-fluorouracil through suppression of the PI3K/Akt/NF-κB pathway.

Authors:  Yuan Fang; Zongtao Chai; Dansong Wang; Tiantao Kuang; Wenchuan Wu; Wenhui Lou
Journal:  Mol Cell Biochem       Date:  2014-10-28       Impact factor: 3.396

5.  Molecular alterations in the carcinogenesis and progression of hepatocellular carcinoma: Tumor factors and background liver factors.

Authors:  Yoshikuni Inokawa; Kenichi Inaoka; Fuminori Sonohara; Masamichi Hayashi; Mitsuro Kanda; Shuji Nomoto
Journal:  Oncol Lett       Date:  2016-09-15       Impact factor: 2.967

6.  Structural rationale for the cross-resistance of tumor cells bearing the A399V variant of elongation factor eEF1A1 to the structurally unrelated didemnin B, ternatin, nannocystin A and ansatrienin B.

Authors:  Pedro A Sánchez-Murcia; Álvaro Cortés-Cabrera; Federico Gago
Journal:  J Comput Aided Mol Des       Date:  2017-09-12       Impact factor: 3.686

7.  Eukaryotic elongation factor-1α 2 knockdown inhibits hepatocarcinogenesis by suppressing PI3K/Akt/NF-κB signaling.

Authors:  Fu-Nan Qiu; Yi Huang; Dun-Yan Chen; Feng Li; Yan-An Wu; Wen-Bing Wu; Xiao-Li Huang
Journal:  World J Gastroenterol       Date:  2016-04-28       Impact factor: 5.742

8.  AKTions by Cytoplasmic lncRNA CASC9 Promote Hepatocellular Carcinoma Survival.

Authors:  Ji Heon Noh; Myriam Gorospe
Journal:  Hepatology       Date:  2018-10-11       Impact factor: 17.425

9.  The complexity of p53-mediated metabolic regulation in tumor suppression.

Authors:  Yanqing Liu; Wei Gu
Journal:  Semin Cancer Biol       Date:  2021-03-27       Impact factor: 17.012

10.  Role of PI3K/AKT Signaling Pathway in Nucleus Pulposus Cells.

Authors:  Quan Xiao; Yun Teng; Changming Xu; Wei Pan; Hanshi Yang; Jiali Zhao; Quan Zhou
Journal:  Biomed Res Int       Date:  2021-07-01       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.